Novel “SMARTer” Clinical Trial Design Improves Odds of Approval and Can Reduce Study Size By Over 80%: Modeling Use of a ctDNA “Optimizing Diagnostic” for Early Therapy Switching in Immuno-Oncology Trials
doi: https://doi.org/10.1101/2023.02.20.23286152
